However, this poses a challenge with CDC25 as there are 3 forms of the protein with slightly different structures and it has been shown that suppression of one may suppress the tumour growth but may not be sufficiently powerful to move forward into clinical testing and development of a ready-for-market treatment. This evidence concerns the gene CDC25C and neoplasm.